ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma

He Ming Ming; Zhang Dong Sheng; Wang Feng; Wang Zhi Qiang; Luo Hui Yan; Ren Chao; Jin Ying; Chen Dong Liang; Xu Rui Hua*
World Journal of Gastroenterology2014-1-7DOI: 10.3748/wjg.v20.i1.264
1被引12阅读
引用收藏
分享

摘要

AIM: To investigate adjuvant chemotherapy, p53 and carcinoembryonic antigen (CEA) expression and prognosis after D2 gastrectomy for stage I/II gastric adenocarcinoma. <br>METHODS: A total of 286 patients with stage. or. gastric adenocarcinoma who underwent D2 radical gastrectomy between May 2007 and December 2010 were enrolled into this study. One hundred and sixty-nine of these patients received surgery plus adjuvant chemo-therapy, and 117 patients received surgery alone. Tumor expression of p53 and CEA proteins in all patients was evaluated immunohistochemically and correlated with clinicopathological parameters. The Kaplan-Meier curves for overall survival (OS) and disease-free survival (DFS) with log-rank testing were used to compare the survival difference. A Cox proportional hazard regression model was used for multivariate analysis. <br>RESULTS: Patients with adjuvant chemotherapy had a significantly better median OS (50.87 mo vs 30.73 mo, P = 0.000) and median DFS (36.30 mo vs 25.60 mo, P = 0.001) than patients with surgery alone in the entire cohort. Consistent results with the entire cohort were found in stage. (P = 0.006 and P = 0.047), stage. (P = 0.005 and P = 0.030), and stage III B/III C patients (P = 0.000 and P = 0.001). The median OS and DFS advantages were confirmed by multivariate analysis (P = 0.000 and P = 0.008) and maintained when the analyses were restricted to fluoropyrimidine monotherapy (P = 0.003 and P = 0.001) and fluoropyrimidine plus platinum regimen (P = 0.001 and P = 0.007), however, not the fluoropyrimidine plus taxane (P = 0.198 and P = 0.777) or platinum plus taxane (P = 0.666 and P = 0.687) regimens. Median OS and median DFS did not differ significantly between the patients with p53(+) and p53(-) tumors (P = 0.608 and P = 0.064), or between patients with CEA(+) and CEA(-) tumors (P = 0.052 and P = 0.989), which were maintained when the analyses were restricted to surgery alone (p53: P = 0.864 and P = 0.431; CEA: P = 0.142 and P = 0.948), adjuvant chemotherapy (p53: P = 0.802 and P = 0.091; CEA: P = 0.223 and P = 0.946) and even different chemotherapy regimens (P > 0.05). <br>CONCLUSION: Patients after D2 gastrectomy for stage II/III gastric adenocarcinoma had significantly better survival after fluoropyrimidine monotherapy and fluoropyrimidine plus platinum. p53 and CEA were not prognostic.

学科与关键词

关键词
Gastric adenocarcinomaAdjuvant chemotherapyp53Carcinoembryonic antigenImmunohistochemistry
相关
加载中…
  • Survival analysis of elderly patients over 65 years old with stage II/III gastric cancer treated with adjuvant chemotherapy after laparoscopic D2 gastrectomy: a retrospective cohort study
    Liang, Yanrui*; Zhao, Liying; Chen, Hao; Lin, Tian; Chen, Tao; Zhao, Mingli; Hu, Yanfeng; Yu, Jiang; Liu, Hao; Li, GuoxinBMC CANCER, 2021, 21(1): 196.被引 10
  • Adjuvant Chemotherapy for Patients with Adenocarcinoma of the Esophagogastric Junction: A Retrospective, Multicenter, Observational Study
    Nie, Run-Cong; Luo, Tian-Qi; Li, Guo-Dong; Zhang, Fei-Yang; Chen, Guo-Ming; Li, Jin-Xing; Chen, Xiao-Jiang; Zhao, Zhou-Kai; Jiang, Kai-Ming; Wei, Yi-Cheng; Huang, Ming-Wei*; Chen, Shi*; Chen, Ying-Bo*Annals of Surgical Oncology, 2022.被引 2
  • Association of O6-Methylguanine-DNA Methyltransferase Protein Expression With Postoperative Prognosis and Adjuvant Chemotherapeutic Benefits Among Patients With Stage II or III Gastric Cancer.
    Cao Yifan; Liu Hao; Li He; Lin Chao; Li Ruochen; Wu Songyang; Zhang Heng; He Hongyong; Zhang Weijuan; Xu JiejieJAMA Surgery, 2017.
查看全部 →

发表信息

论文状态
公开发表
期刊
World Journal of Gastroenterology
发表日期
2014-01-07
卷期
第 20 卷, 第 1 期
页码
264-273
DOI
10.3748/wjg.v20.i1.264
语言
ENGLISH
期刊收录
SCIE
期刊等级
Q2
成果收录
SCI
资助标注
National High Technology Research and Development Program of China (863 Program), China [2012AA02A506]; Science and Technology Department of Guangdong Province, China [2012B031800088]; Medical Scientific Research Foundation of Guangdong Province, China [C2011019]

作者

  • H

    He Ming Ming (第一作者)

  • Z

    Zhang Dong Sheng

查看全部 9 位作者收起作者
  • W

    Wang Feng

  • W

    Wang Zhi Qiang

  • L

    Luo Hui Yan

  • R

    Ren Chao

  • J

    Jin Ying

  • C

    Chen Dong Liang

  • X

    Xu Rui Hua (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417